Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Mild Vascular Cognitive Impairment
NCT03306979Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2018
- Primary completion
- Sep 2023
- Countries
- 1
- Sponsor
- Sunnybrook Health Sciences Centre
- Modality
- Small Molecules
- Drugs
- acetylcysteine
- Conditions
- vascular cognitive impairment (VCI)
01
Overview
Phase 2, randomised, double-blind trial in vascular cognitive impairment (VCI) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Change in Executive Function at 6 months. Started Apr 2018; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
N-acetylcysteine
NAC 2400 mg daily (titrated)
Placebo
Matching placebo
03
Endpoints
Primary
Change in Executive Function
Secondary
Change in Processing Speed
Change in Memory
Beyond the preview
Go deeper on NCT03306979.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306979.